Oppenheimer & Co. Inc. Acquires 6,318 Shares of Tyra Biosciences, Inc. (NASDAQ:TYRA)

Oppenheimer & Co. Inc. increased its holdings in Tyra Biosciences, Inc. (NASDAQ:TYRA) by 9.0% in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 76,806 shares of the company’s stock after purchasing an additional 6,318 shares during the period. Oppenheimer & Co. Inc. owned approximately 0.15% of Tyra Biosciences worth $1,806,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Rhumbline Advisers raised its holdings in shares of Tyra Biosciences by 12.3% in the 2nd quarter. Rhumbline Advisers now owns 23,572 shares of the company’s stock worth $377,000 after buying an additional 2,574 shares in the last quarter. SG Americas Securities LLC acquired a new stake in Tyra Biosciences in the 3rd quarter valued at $311,000. Bank of New York Mellon Corp grew its position in Tyra Biosciences by 32.8% in the second quarter. Bank of New York Mellon Corp now owns 58,087 shares of the company’s stock valued at $929,000 after acquiring an additional 14,352 shares during the period. HighVista Strategies LLC acquired a new position in Tyra Biosciences during the second quarter worth $257,000. Finally, Vanguard Group Inc. lifted its holdings in shares of Tyra Biosciences by 18.6% during the first quarter. Vanguard Group Inc. now owns 899,800 shares of the company’s stock valued at $14,757,000 after acquiring an additional 140,833 shares during the period. Institutional investors own 84.14% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on the stock. HC Wainwright lowered their target price on shares of Tyra Biosciences from $32.00 to $30.00 and set a “buy” rating on the stock in a report on Monday, November 11th. Wedbush reaffirmed an “outperform” rating and set a $28.00 price objective on shares of Tyra Biosciences in a report on Friday, October 25th. Bank of America raised Tyra Biosciences from a “neutral” rating to a “buy” rating and boosted their target price for the stock from $22.00 to $31.00 in a report on Friday, October 18th. Piper Sandler started coverage on Tyra Biosciences in a report on Thursday, August 15th. They set an “overweight” rating and a $33.00 price target for the company. Finally, Oppenheimer boosted their price objective on Tyra Biosciences from $25.00 to $33.00 and gave the stock an “outperform” rating in a research note on Thursday, September 19th. Five research analysts have rated the stock with a buy rating, According to MarketBeat.com, Tyra Biosciences has a consensus rating of “Buy” and an average target price of $31.00.

Insider Transactions at Tyra Biosciences

In other Tyra Biosciences news, CFO Alan Fuhrman acquired 9,500 shares of Tyra Biosciences stock in a transaction on Wednesday, October 30th. The shares were purchased at an average cost of $16.00 per share, with a total value of $152,000.00. Following the completion of the purchase, the chief financial officer now owns 12,849 shares in the company, valued at $205,584. The trade was a 283.67 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Todd Harris sold 5,698 shares of the company’s stock in a transaction on Thursday, September 19th. The shares were sold at an average price of $24.31, for a total transaction of $138,518.38. Following the sale, the chief executive officer now owns 1,496,729 shares of the company’s stock, valued at $36,385,481.99. The trade was a 0.38 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 101,050 shares of company stock worth $2,235,492 in the last quarter. 15.40% of the stock is owned by company insiders.

Tyra Biosciences Stock Performance

NASDAQ:TYRA opened at $15.39 on Monday. The company has a market cap of $778.73 million, a price-to-earnings ratio of -9.56 and a beta of 1.08. The stock’s fifty day moving average price is $21.31 and its two-hundred day moving average price is $19.98. Tyra Biosciences, Inc. has a 52-week low of $10.60 and a 52-week high of $29.60.

Tyra Biosciences (NASDAQ:TYRA) last issued its quarterly earnings results on Thursday, November 7th. The company reported ($0.41) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.40) by ($0.01). On average, equities analysts predict that Tyra Biosciences, Inc. will post -1.57 EPS for the current fiscal year.

About Tyra Biosciences

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.